Why the ResMed (ASX:RMD) share price just hit an all-time high

A confluence of factors are pushing its share price higher.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The ResMed Inc.(ASX: RMD) share price is breaking new records.

At the time of writing, shares in the healthcare company are trading for $35.28 – up 0.54%. At one point, shares reached an intraday and all-time high of $35.44.

The S&P/ASX 200 Index (ASX: XJO) is also having a record day. Presently, the benchmark index is 0.05% higher but reached a high of 7,417.6 points. While the influence of the general market on the ResMed share price could be having an effect, there may be more to the story.

Let's take a closer look.

four excited doctors with their hands in the air

Image source: Getty Images

Healthcare shares are looking fit

Throughout July, ASX healthcare shares, like ResMed, have been surging. Just in the last month, the ResMed share price has jumped 8.1%, Sonic Healthcare Limited (ASX: SHL) improved 8.2% and CSL Limited (ASX: CSL) shares are up 1.5%.

With COVID back in the spotlight, as the delta variant causes a sharp increase in cases across the world, healthcare shares – including ResMed – may be the few to benefit from this strain of the virus.

Experts too have had nothing but positive words to say about the ResMed share price in recent days.

Analysts at Macquarie Group, for example, say ResMed is a growth share for investors to buy right now. Randal Jenneke, head of Australian equities at T Rowe Price Group, says ResMed is a "quality" share for investors.

Jenneke previously said

Over more than two decades of data for the Australian market, high quality had outperformed low quality by 6.7% per annum.

… [quality shares like ResMed are] poised to outperform over the coming year.

As the ResMed share price has just hit a 52-week high, this advice is being borne out – at least for the time being.

Another factor potentially helping ResMed shares – the falling Aussie dollar.

Experts are tipping it to fall below 70 cents against the greenback. For ASX listed companies that predominately do business in the US, this could be a windfall.

ResMed is one of those companies that predominantly trade in the US. In fact, it is a dual listed company with shares on the New York Stock Exchange.

ResMed share price snapshot

Over the past 12 months, the ResMed share price has increased 23.1%. Year-to-date it is up an even greater 28.3%.

ResMed has a market capitalisation of around $51 billion.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has recommended ResMed Inc. and Sonic Healthcare Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Scientists in a laboratory look at a computer screen with anticipation on their faces.
Healthcare Shares

Down 30% today, is it time to buy into this beaten-down biotech share?

While there's been bad news, this company has more irons in the fire.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

What's the impact of US tariffs on Aussie drugmakers CSL and Mayne Pharma?

Is the US' bark worse than its bite?

Read more »

Health professional working on his laptop.
Healthcare Shares

Mesoblast shares are back in the red on Tuesday. Here's why

Mesoblast shares slip despite another strong quarterly sales update from Ryoncil.

Read more »

A smiling businessman in the city looks at his phone and punches the air in celebration of good news.
Earnings Results

Why are Telix shares jumping 8% today?

The radiopharmaceuticals company's shares are starting the week strongly.

Read more »

A company manager presents the ASX company earnings report to shareholders at an AGM.
Healthcare Shares

Mesoblast shares: Ryoncil® underpins strong earnings growth

Mesoblast shares are in focus as Ryoncil® delivers nearly US$100m in sales since launch, fueling future growth initiatives.

Read more »

medical asx share price represented by doctor giving thumbs up
Healthcare Shares

Telix Pharmaceuticals Q1 2026: Revenue growth, guidance reaffirmed

Telix Pharmaceuticals lifts Q1 revenue 11%, reports pipeline progress, and keeps its full-year guidance on track.

Read more »

Five healthcare workers standing together and smiling.
Healthcare Shares

3 ASX 200 healthcare shares to buy amid sector rout

The experts are backing these stocks for price growth.

Read more »

Researchers and doctors with futuristic 3D hologram overlay for body anatomy or DNA in hospital clinic.
Healthcare Shares

Are investors taking a big gamble chasing 4DX shares higher and higher?

Investor interest in this ASX healthcare tech stock is booming.

Read more »